血清MMP-3在慢性肾脏病中的临床价值
该研究采用高敏时间分辨荧光免疫分析法检测237例CKD患者和96名健康人的血清MMP-3水平,发现CKD患者显著升高且与eGFR、CREA、BUN及蛋白肌酐比相关;40.39 ng/mL临界值联合eGFR可有效识别早期(G1+G2)CKD阳性患者,阳性率73.45%。
要点
- CKD患者血清MMP-3显著高于健康对照,且随肾功能下降而升高。
- MMP-3与eGFR、CREA、BUN及蛋白肌酐比显著相关,CREA、BUN、MMP-3对疾病严重度影响最显著。
- 40.39 ng/mL联合eGFR可辅助诊断早期CKD,早期患者MMP-3>100 ng/mL者肾损伤和炎症更重。
核心结论
- 血清MMP-3升高与CKD进展中肾功能下降相关,合并炎症者可能表达高水平MMP-3。
- 血清MMP-3可能辅助eGFR改善早期CKD患者的诊断。
研究设计与样本
- 研究纳入237例CKD患者和96名健康个体,采用高敏时间分辨荧光免疫分析法定量血清MMP-3水平。
- 分析不同CKD分期MMP-3水平差异及其与临床指标的相关性。
主要发现
- CKD患者血清MMP-3浓度为171.76 ± 165.22 ng/mL,显著高于健康对照的34.05 ± 22.93 ng/mL(P < 0.0001)。
- 血清MMP-3与eGFR呈负相关(r = -0.5804,P < 0.0001),与CREA(r = 0.5823,P < 0.0001)、BUN(r = 0.6106,P < 0.0001)、蛋白肌酐比(r = 0.4992,P < 0.0001)呈正相关。
- 随机森林分析显示CREA、BUN和MMP-3对CKD疾病严重度影响最显著。
- MMP-3临界值40.39 ng/mL联合eGFR诊断早期(G1+G2)CKD阳性患者的阳性率为73.45%。
- 早期CKD患者中血清MMP-3 > 100 ng/mL者较MMP-3较低者肾损伤和炎症更严重。
关键数值与推荐
- 血清MMP-3临界值40.39 ng/mL联合eGFR用于诊断早期(G1+G2)CKD阳性患者,阳性率73.45%。
- 早期CKD患者血清MMP-3 > 100 ng/mL提示更严重的肾损伤和炎症。
临床怎么用
- 血清MMP-3可作为辅助eGFR诊断早期CKD的实验室指标。
- 对早期CKD患者,MMP-3 > 100 ng/mL提示肾损伤和炎症更重,需加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic kidney disease (CKD) is defined as the progressive deterioration of renal parenchyma and decline in renal unit function. In the early stages of CKD(G1 + G2), symptoms are usually not obvious and cannot be effectively recognized on the basis of available clinical markers. Progression to the middle and late stages of CKD results in severe kidney damage with multiple complications causing adverse outcomes, including death. Therefore, the early diagnosis and monitoring of CKD is critical. Matrix metalloproteinase-3 (MMP-3), an extracellular matrix-degrading enzyme, plays an important role in kidney diseases. However, the clinical significance of serum MMP-3 levels in CKD has rarely been reported. METHODS: We quantified the serum MMP-3 levels of 237 patients with CKD and 96 healthy individuals by using a highly sensitive time-resolved fluorescence immunoassay and analyzed differences in MMP-3 levels among the stages of CKD and the correlations of these changes with clinical indicators. RESULTS: The serum MMP-3 concentrations of patients with CKD (171.76 ± 165.22 ng/mL) were significantly higher than those of healthy controls (34.05 ± 22.93 ng/mL; P < 0.0001). In CKD, serum MMP-3 levels were significantly correlated with estimated glomerular filtration rate (eGFR) (r = - 0.5804, P < 0.0001), serum creatinine (CREA) (r = 0.5823, P < 0.0001), blood urea nitrogen (BUN) (r = 0.6106, P < 0.0001), and protein-to-creatinine ratio (r = 0.4992, P < 0.0001). Randomized forest analysis finds CREA, BUN, and MMP-3 most significant influences on CKD disease severity. The critical value of MMP-3 concentration of 40.39 ng/mL combined with eGFR was effective in diagnosing positive patients in the early (G1 + G2) stage of CKD and showed a positivity rate of 73.45 %. Moreover, in the early stages of CKD, patients with CKD who had serum MMP-3 concentration > 100 ng/mL had more severe renal impairment and inflammation than those with CKD who have lower serum MMP-3 concentrations. CONCLUSION: Elevated serum MMP-3 levels are correlated with decreased kidney function in CKD progression, and patients with concomitant inflammation may express high levels of serum MMP-3. Serum MMP-3 may assist eGFR in improving the diagnosis of patients with early CKD.
引用
- Fu Y, Song C, Qin Y, et al. Clinical value of serum MMP-3 in chronic kidney disease. Clin Chim Acta. 2023. PMID: 38128817. doi:10.1016/j.cca.2023.117725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。